About Boston Biomedical

Company Background

Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. As a fully integrated oncology drug research and development company, Boston Biomedical, Inc. has established a track record of accomplishments, including advancing the research and development of multiple compounds and clinical programs. The company’s range of expertise includes drug discovery, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing, and control), global clinical trials, regulatory affairs and commercialization.

Headquartered in Cambridge, Massachusetts, Boston Biomedical, Inc. is wholly owned by Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. In 2017, Sumitomo Dainippon Pharma acquired Tolero Pharmaceuticals, a U.S.-based biotechnology company specializing in research and development of therapeutic agents in the areas of oncology and hematological disorders. This acquisition expanded Sumitomo Dainippon Pharma’s global oncology and hematology portfolios. Together, the companies – Sumitomo Dainippon Pharma Co., Ltd., Boston Biomedical and Tolero – work to expedite drug discovery, development and commercialization of innovative treatments for cancer. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes.

Company Leadership

Industry veteran Patricia S. Andrews was appointed to the role of Chief Executive Officer in 2017. Since joining the company in 2013, Ms. Andrews has been a key driving force to lead the company forward into the next stage of growth and innovation through expanding its robust clinical pipeline, initiating additional clinical studies for its investigational compounds across multiple tumor types, and setting the foundation for future commercialization of late-stage compounds.

Edgar Braendle, MD, PhD, joined Boston Biomedical in 2017 as Executive Vice President, Head of Research and Development and Chief Medical Officer and is responsible for leading the company’s discovery research and clinical strategies. Dr. Braendle’s extensive oncology industry experience has been instrumental in steering the direction of the company’s clinical pipeline.

Dee Mahoney, Senior Vice President and Chief Commercial Officer, leads the company’s commercialization efforts. Since joining Boston Biomedical in 2017, Ms. Mahoney has progressed the commercial strategy for the company’s investigational therapeutics to target oncogenic pathways including cancer stemness inhibitors, cancer vaccine compounds and other oncology assets in development for the North American market.

R&D Focus

The company’s most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses.

Our most advanced research compound, napabucasin (BBI-608), is an orally-administered investigational agent that affects multiple oncogenic cellular pathways, including inhibition of the STAT3 pathway, which has been implicated in viability of cancer cells and cancer cells with stemness phenotypes.

Recently, the Company advanced DSP-7888 (ombipepimut-S*) into clinical trials. DSP-7888 is an investigational cancer peptide vaccine containing peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTL) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic and solid tumors. Researchers have identified that by adding helper T cell inducing peptides, improved outcomes may be achieved compared to a killer peptide treatment regimen alone.

*Adegramotide/nelatimotide is also assigned as its international nonproprietary name (INN).

Path Ahead

With a robust pipeline across various stages of clinical development and multiple phase 3 trials underway for napabucasin, Boston Biomedical, Inc. continues to build its commercial capabilities. A core group of seasoned professionals is in place, and the company will continue to expand and grow as its research programs mature.

Boston Biomedical, Inc. has created a unique corporate environment, leveraging its innovation-driven culture, scientific leadership, and drug development expertise to advance the development of novel therapeutics for patients with cancer. Click here to learn more about career opportunities.